Navigation Links
Pharmasset Announces Intent to Amend QUANTUM Trial
Date:12/16/2011

PRINCETON, N.J., Dec. 16, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that the company will amend the design of the QUANTUM Phase 2b trial of the guanine nucleotide analog PSI-938 and discontinue all treatment arms with a regimen containing PSI-938. There are 235 individuals with hepatitis C virus (HCV) in the study who are receiving treatment with PSI-938 alone or in combination with PSI-7977 or PSI-7977 and ribavirin.  During routine safety monitoring, the company detected laboratory abnormalities associated with liver function in subjects receiving PSI-938 300 mg once daily.  These laboratory abnormalities have not been observed in patients receiving PSI-7977 and ribavirin in the QUANTUM study or in other trials evaluating PSI-7977.  Both the 12 and 24-week PSI-7977 and ribavirin arms will continue unchanged, data from which will support  NEUTRINO, an interferon free, 12-week Phase 3 study of PSI-7977 and ribavirin in patients with HCV genotype 1 (GT-1).  

The subject of today's announcement does not trigger the "key product event" clause set forth in section 4.1(t) of the Agreement and Plan of Merger entered into by Pharmasset and Gilead Sciences, Inc. on November 21, 2011 and does not alter either party's rights and obligations under the terms of the agreement. Pharmasset anticipates that the transaction announced on November 21, 2011 will conclude in the first quarter of 2012.

About Pharmasset
Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. Our research and development efforts are focused on nucleoside/tide analogs, a class of compounds which act as alternative substrates for
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
2. Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C
3. Pharmasset to Present at Two Upcoming Conferences
4. Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
5. Pharmasset Announces Two-for-One Forward Stock Split
6. Pharmasset to Present at Canaccord Genuity Growth Conference
7. Pharmasset Reports Fiscal Third Quarter 2011 Financial Results
8. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
9. Pharmasset to Present at Two Upcoming Investor Conferences
10. Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
11. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... 17, 2013 Actavis, Inc. (NYSE: ACT ... reversed the decision of the U.S. Court of Appeals for ... granting Actavis, motion to dismiss the Federal Trade Commission,s lawsuit, ... was the result of a decision by a 5 to ... approach and adopted the traditional "rule of reason" as the ...
(Date:6/17/2013)... Israel , June 17, 2013 ... Board of Governors of the Israel-U.S. Binational Industrial Research ... in funding for fourteen new projects between Israeli and ... BIRD , the projects will access private sector funding, ... $33 million. The semi-annual meeting was held at the ...
(Date:6/17/2013)... , June 17, 2013  Ochsner Health System ... that will help improve medication safety by simplifying ... health system. The CareFusion Pyxis ... hardware and software that helps hospitals significantly reduce ... administer medications because of simpler, more efficient workflows. ...
Breaking Medicine Technology:U.S. Supreme Court Reverses U.S. Court of Appeals Decision in FTC v. Actavis 2U.S. Supreme Court Reverses U.S. Court of Appeals Decision in FTC v. Actavis 3BIRD - Israel - U.S. Binational Industrial R&D Foundation to Invest $11 Million in 14 new Projects 2BIRD - Israel - U.S. Binational Industrial R&D Foundation to Invest $11 Million in 14 new Projects 3BIRD - Israel - U.S. Binational Industrial R&D Foundation to Invest $11 Million in 14 new Projects 4Ochsner Health System Improves Safety Through Advanced Medication Management Technology 2Ochsner Health System Improves Safety Through Advanced Medication Management Technology 3Ochsner Health System Improves Safety Through Advanced Medication Management Technology 4Ochsner Health System Improves Safety Through Advanced Medication Management Technology 5
... Va., March 3, 2011 Insmed Incorporated (Nasdaq: ... the Pediatric Committee of the European Medicines Agency (EMA) ... Investigation Plan (PIP) for ARIKACE™ (liposomal amikacin for inhalation), ... Pseudomonas and non-TB mycobacteria (NTM) lung infections.  The ...
... Ltd. (Nasdaq: SVA ), a leading provider ... the application to commence clinical trials for its 13-valent ... Drug Administration (SFDA) on March 3, 2011. ... The vaccine targets infants under two years old. The ...
Cached Medicine Technology:Insmed Announces European Medicines Agency Acceptance of Its Pediatric Investigation Plan for ARIKACE™ in the Cystic Fibrosis Pseudomonas Indication 2Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV) 2Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV) 3Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV) 4
(Date:6/18/2013)... June 18, 2013 The Columbia Center ... area premier of SHREK The Musical July 18-21 ... Oscar®-winning DreamWorks film that started it all, SHREK is the ... stage. In a faraway kingdom turned upside down, things ... prince – shows up to rescue a feisty princess. Throw ...
(Date:6/18/2013)... 18, 2013 For as long as ... tests, drug testees have found ways to cheat them. ... will find a seemingly fool-proof method for detecting a ... way to get around it. One need only consider ... doping program involved a world-wide network of physicians and ...
(Date:6/18/2013)... Vet Supply Source is pleased to announce the winner of ... a $200 Visa gift card in the random drawing after ... contest. The contest provided customers a fun way to get ... services. , “We hope our customers will continue to ... product deals and specials,” says Jill Metz, a media spokesperson ...
(Date:6/18/2013)... June 18, 2013 The new swab, ... fluid retention through the tip allowing for faster collection ... Salimetrics Infant Swab (SIS) can be tested for ... A. , The diameter of the Salimetrics Infant Swab ... new swab to access more saliva in the newborn’s ...
(Date:6/17/2013)... 18, 2013 The timeless art of Skin Brushing ... says Sublime Beauty®. Why? Because the simple act of ... brush can contribute strongly to overall general health. , The skin ... age, the skin is less able to throw off these dead ... contribute to poor skin quality and bring down well-being. Dry body ...
Breaking Medicine News(10 mins):Health News:Everyone’s Favorite Ogre Coming to Town! CCTA’s Teen Professional Theatre Offers Area Premier of SHREK The Musical 2Health News:ATAGO Urine Specific Gravity Refractometers Continue to Catch Drug Test Cheaters 2Health News:ATAGO Urine Specific Gravity Refractometers Continue to Catch Drug Test Cheaters 3Health News:Vet Supply Source Announces Sweepstakes Contest Winner 2Health News:Salimetrics Redesigns Infant Swab for Faster, Easier Collection 2Health News:Skin Brushing Boosts Blood Circulation for Better Health, says Sublime Beauty®; Skin Brushes Back in Stock Now 2
... second counts when performing CPR. A new study has ... cardiac arrest outside a hospital drops significantly if the pause ... electric shock is longer than 20 seconds. The number ... less than 10 seconds. "If your pre-shock pause ...
... -- Cardiac arrest victims are more likely to survive if ... using a defibrillator to deliver an electric shock to the ... of 815 American and Canadian patients who suffered sudden cardiac ... using either an automated external defibrillator or a manual defibrillator. ...
... team of Wayne State University researchers was awarded $330,000 ... 3-D neural probe. Their aim is to develop an ... that affects more than 250 million people worldwide. ... neuroscience and neurosurgery, there is an increasing need for ...
... Acta Obstetricia et Gynecologica Scandinavica (AOGS) reveals that ... 39 to week 41, is not connected with higher rates ... or induced labor. There has been much debate about this ... to expectant management might lead to a higher risk for ...
... Medicine (BUSM) have found that among HIV-infected adults with ... a poor and inaccurate method for detecting unhealthy drinking. ... . Unhealthy alcohol use is common in HIV-infected ... lower CD4 cell count and can cause hepatic injury. ...
... ON (June 20, 20122) - Women with urinary incontinence ... develop postpartum depression as those without incontinence, according to ... in McMaster University,s School of Nursing. Postpartum depression ... in the family. According to the Canadian Mental Health ...
Cached Medicine News:Health News:Increase in survival when AED used less than 10 seconds after CPR pause 2Health News:Faster Transition From CPR to Defibrillator May Save Lives 2Health News:Wayne State University researchers win grant from the NSF to target tinnitus 2Health News:Wayne State University researchers win grant from the NSF to target tinnitus 3Health News:Inducing labor is not associated with higher rates of cesarean sections 2Health News:Researchers find CDT biomarker ineffective for identifying unhealthy alcohol use 2Health News:Urinary incontinence doubles risk of postpartum depression 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: